← Back to Home

Pan-RAS drug shows tumor shrinkage signal in pancreatic cancer as Erasca brings forward plans for a 2027 Phase 3 trial

ERAS-0015 achieved a confirmed objective response rate of 44% in 25 previously treated patients with pancreatic cancer. These early results are driving the company to accelerate development, but more complete evidence is still needed to determine how long the effects last and whether patients receiving first-line treatment can benefit.

By SURL BioNews

Early tumor shrinkage results for an investigational pancreatic cancer drug are accelerating its development timeline. In a filing submitted to the U.S. Securities and Exchange Commission on November 20, Erasca announced that it had brought forward the planned start of a Phase 3 trial of its pan-RAS drug candidate ERAS-0015 in first-line pancreatic cancer to the first half of 2027. This is the company's trial plan; it does not mean efficacy has been established or the drug has been approved for use.

The update comes from the Phase 1 AURORAS-1 trial. Among 25 previously treated patients with pancreatic ductal adenocarcinoma harboring KRAS G12X mutations who received 32 mg of ERAS-0015 daily, 11 had confirmed objective responses, for a response rate of 44%; 84% of these patients were receiving third-line or later treatment.

The objective response rate measures whether tumor shrinkage meets predefined criteria and cannot be directly translated into a survival benefit. The company said all 11 responding patients remained on treatment, but continued treatment alone is not enough to establish how long the effects last. The data cutoff for monotherapy was September 1, 2026, and some responses were confirmed only after that date.

An evidence gap remains between monotherapy results in later-line patients and first-line treatment. The company is also exploring ERAS-0015 in combination with gemcitabine and nab-paclitaxel; as of October 14, the 16 mg cohort had cleared the dose-limiting toxicity observation period, and dosing was underway in the 24 mg cohort, but efficacy data for this combination had not yet been released.

Safety also affects further development. Among 54 participants receiving 32 mg daily, treatment-related adverse events led to dose interruptions in 13% and dose reductions in 16.7%. The filing also reiterated a previously disclosed death involving pneumonitis: a patient receiving 24 mg discontinued treatment and received management after developing Grade 3 pneumonitis, subsequently had supportive care withdrawn at their own request, and ultimately died.

The clearest significance of this update, therefore, is that it provides a rationale for further validation. The pancreatic cancer cohort of 25 patients is limited in size, and no randomized controlled comparison was provided; the response rate for later-line monotherapy cannot directly predict first-line treatment outcomes, much less establish superiority over existing therapies.

The key questions now are how the Phase 3 trial will be designed and whether longer follow-up can support both the durability of efficacy and safety. The current evidence comes from the company's regulatory filing, without independent corroboration of the same developments; accelerating the trial timeline represents a step forward in development decisions, while how much actual benefit patients may receive remains a question for subsequent trials.

References

  1. Erasca / SEC filing